|

Carboplatin or Cisplatin Clinical Trials

5 actively recruiting trials across 1 location

Also known as: chemotherapeutic drug

Pipeline

Phase 2: 3Phase 3: 1Phase 4: 1

Top Sponsors

  • University of Illinois at Chicago1
  • The Affiliated Hospital of Qingdao University1
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1
  • Shanghai Junshi Bioscience Co., Ltd.1
  • Second Hospital of Shanxi Medical University1

Indications

  • Lung Cancer5
  • Cancer5
  • Metastatic Squamous Non-Small Cell Lung Carcinoma1
  • Non-Squamous Non-Small Cell Lung Cancer1
  • Non-small Cell Lung Cancer (NSCLC)1

Other4 trials

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase 2
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
Phase 4
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Phase 2

Chicago, Illinois1 trial

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Ryan Nguyen

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.